<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124226</url>
  </required_header>
  <id_info>
    <org_study_id>METGINA-005</org_study_id>
    <nct_id>NCT02124226</nct_id>
  </id_info>
  <brief_title>Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma</brief_title>
  <official_title>Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita degli Studi di Catania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universita degli Studi di Catania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic severe asthma (CSA) have a crippling disease and current available&#xD;
      treatments are not satisfactory. Thus, management of CSA remains a major unmet need. Although&#xD;
      the evidence from existing randomized controlled trials fails to support a definite role for&#xD;
      immunomodulatory drugs in these patients due to major methodologic drawbacks, findings with&#xD;
      low-dose methotrexate (MTX) are encouraging. However, larger and well designed clinical&#xD;
      trials are required to establish the beneficial role of MTX in CSA and for the detection of&#xD;
      the key characteristics of those who are going to respond to this drug.&#xD;
&#xD;
      This study will be the first multi-centre RCT investigating the role of an add-on&#xD;
      immunological modifier as a clinically useful therapeutic strategy in patients with&#xD;
      well-phenotyped chronic severe asthma. As such, this study does not overlap with any other&#xD;
      research currently ongoing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited from the accessible asthmatic patients lists of tertiary referral&#xD;
      centers. All patients will meet the stringent diagnostic criteria for CSA, including the&#xD;
      requirement for the regular use of Step 5 medications (i.e. oral prednisone and/or&#xD;
      omalizumab). The experimental design of the proposed study will take the form of a&#xD;
      double-blind parallel-randomized placebo-controlled trial consisting of a total of eight&#xD;
      visits including run-in and run-out periods. Patients will be randomly allocated to receive&#xD;
      either MTX or matched placebo once a week as add-on therapy to their existing medication&#xD;
      after run-in. Physiological, laboratory and clinical assessments will be measured regularly&#xD;
      throughout the study and compared with baseline assessments.&#xD;
&#xD;
      We expect that MTX will reduce Step 5 medications dosage in patients with CSA without&#xD;
      compromising the overall disease control. Improvement in several indicators of asthma&#xD;
      severity and control will be also investigated&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>At least 50% reduction in total dosage of GINA step 5 medications</measure>
    <time_frame>80 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinically significant changes in clinimetric scores</measure>
    <time_frame>80 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Low Dose Methotrexate in Severe Chronic Asthma</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of 7.5 mg/week + folic acid the day after for 3 weeks as add-on therapy to their existing medication. Study treatment dosage will be increased, the maintenance dose will be 10 mg/week + folic acid the day after for 27 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>7.5 mg/week + folic acid the day after</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <other_name>Several brand names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>Matched placebo</arm_group_label>
    <other_name>matched placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients with a diagnosis of CSA taking GINA Step 5 medications (i.e. regular OCS&#xD;
             and/or omalizumab for a minimum of 6 months);&#xD;
&#xD;
          2. failure in weaning patients completely from Step 5 medications during run-in;&#xD;
&#xD;
          3. male and female individuals age 18 - 75 years;&#xD;
&#xD;
          4. patients must be able to provide consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. use of immunomodulatory therapies in the preceding 3 months;&#xD;
&#xD;
          2. recent or current history of alcoholism;&#xD;
&#xD;
          3. high liver enzyme levels (greater than 2.5 times the upper limit of the normal range);&#xD;
&#xD;
          4. serum creatinine levels greater than 2.0 mg/dL&#xD;
&#xD;
          5. acute illness within 15 days of study medication administration;&#xD;
&#xD;
          6. leucopenia (below 3.0x109/L) and/or thrombocytopenia (below 100x109/L).&#xD;
&#xD;
          7. pregnancy or planning to become pregnant;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riccardo Polosa, Full Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita di Catania</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita degli Studi di Catania</investigator_affiliation>
    <investigator_full_name>Riccardo Polosa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic severe asthma, immunomodulation, methotrexate, steroids, omalizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

